Clinical Trials Directory

Trials / Completed

CompletedNCT02657798

RESIST: Understanding the Role of Depression in Heart Disease

Resist: What Are the Mechanisms Involved in Depression and Antidepressant Resistance That Increase Cardiovascular Risk?

Status
Completed
Phase
Study type
Observational
Enrollment
90 (actual)
Sponsor
University College, London · Academic / Other
Sex
All
Age
18 Years – 74 Years
Healthy volunteers
Accepted

Summary

This study will investigate the biological pathways involved in anti-depressant resistance that increase risk of cardiovascular disease in people with depression.

Detailed description

Rationale: Depression is known to be associated with the development of cardiovascular disease and poorer prognosis after cardiac events, however the mechanisms that mediate these links are poorly understood. Inflammatory and neuroendocrine processes are thought to play an important role in this relationship. In addition, antidepressants have been shown to improve cardiac outcomes and have anti-inflammatory effects, whilst inflammation has been shown to be elevated in patients who do not respond to treatment. Several possible biomarkers for antidepressant resistance have also been demonstrated to be cardiovascular risk markers. These include acute phase inflammatory markers, such as interleukin-6 (IL-6), and hypothalamic-pituitary-adrenal axis (HPA) dysregulation. Design: This will be conducted alongside a larger pharmacological trial, PANDA, where participants will be recruited from primary care and randomized to sertraline (SSRI) or placebo. The RESIST study will compare inflammatory cardiovascular risk factors between depressed patients taking sertraline, depressed patients taking placebo and healthy controls. This will be achieved by investigating the pharmacological effect of antidepressants on gene expression, glucocorticoid and mineralocorticoid receptor function and regulatory T cell (Treg) profiles.

Conditions

Timeline

Start date
2016-06-01
Primary completion
2017-12-01
Completion
2018-11-01
First posted
2016-01-18
Last updated
2020-03-26

Locations

1 site across 1 country: United Kingdom

Source: ClinicalTrials.gov record NCT02657798. Inclusion in this directory is not an endorsement.